Up­dat­ed: 'Close to the mid­dle': Ver­sant launch­es Vec­tor with 'gut­less ade­n­ovirus' de­liv­ery method

Most of the gene ther­a­py world cen­ters around vi­ral vec­tors, but a few biotechs have sprung up in re­cent years to try and avoid the safe­ty is­sues that can come with ade­no-as­so­ci­at­ed virus­es.

A new biotech has emerged to strad­dle some­where “close to the mid­dle,” in the words of Alex May­weg, Ver­sant man­ag­ing di­rec­tor and board mem­ber of the in­cu­ba­tor’s lat­est start­up, Vec­tor Bio­Phar­ma.

Built out of the work of the lab of An­dreas Plück­thun at the Uni­ver­si­ty of Zurich, Vec­tor’s vec­tors in­volve “gut­less ade­n­ovirus,” May­weg told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER